I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Drug Discovery Informatics: A Prelude

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS
Robust Drug Discovery Investments in Response to Growing Global
Disease Burden Provides the Foundation for Growth in the
Market
Growing Global Disease Burden Intensifies the R&D Urgency for
New & Potent Drugs: Global Disease Burden (In Million DALYs:
(Disability-Adjusted Life Years)) for the Years 2015, 2017 &
2019
Rising Drug Development Spending Acts as the Chief Catalyst for
the Adoption of Drug Discovery Informatics: Global
Pharmaceutical R&D Spending (In US$ Billion) for the Years
2017, 2019, 2022 and 2024
Migration to Data Driven Drug Development Provides the
Cornerstone for Growth in the Market
Growing Focus on Optimizing Hit to Lead (H2L) Processes in
Early Stage Drug Discovery to Benefit Growth of Drug Discovery
Informatics/Chemoinformatics
Growing Use of In-Silico Methods in Drug Development Bodes Well
for the Use of Informatics
The Rise of Nanoinformatics as the New Era of Research in
Nanomedicine Marks the Beginning of Use of Informatics in
Nanomedicine
Exploding Commercial Opportunity for Nanomedicine Bodes Well
for the Growth of Nanoinformatics: Global Nanomedicine Market
(In US$ Billion) for the Years 2017, 2019, 2022 and 2024
Cloud Computing Emerges to Play a Key Role in Bioinformatics
Cost Benefits Over In-House Informatics Helps Expand the
Commercial Visibility of Outsourced Informatics
Continuously Evolving CRO Industry Highlights the Growing
Importance & Value of Pharma R&D Outsourcing: Global Contract
Research Organization (CRO) Market (In US$ Billion) for the
Years 2017, 2019, 2022 and 2024
Robust Adoption of Bioinformatics Services Highlights the
Growing Dominance of Informatics Outsourcing Over Traditional
In-House Informatics: Global Bioinformatics Services Market
(In US$ Billion) by Service Type for the Years 2017, 2019,
2022 and 2024
Competitive Challenges Faced by the Pharma Industry & the
Ensuing Need for Decision Support Tools & Collaborative
Discovery Opens the Flood Gates of Opportunity for Drug
Discovery Informatics
Rising Global Healthcare Spending Spurs Government Focus On
Cost Containment Driving Pharma Companies to Cut Drug Prices
by Reducing Research Costs: Global Healthcare Spending (In
US$ Trillion) by Government, Private & Consumer Out-of-
Pocket for the Years 2017, 2019, 2022 and 2025
Productivity Gains, Acceleration of Speed & Success of Drug
Discovery Research Drive Adoption of Drug Discovery
Informatics
Move Towards Value-Based Care & the Resulting Emergence of the
Era of Precision Medicine Catalyzes the Commercial Value of
Drug Discovery Informatics
Robust Outlook for Precision Medicine Strengthens the Business
Case for Drug Discovery Informatics: Global Market for
Precision Medicine (In US$ Billion) for the Years 2017, 2019,
2022 and 2024

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Drug Discovery
Informatics by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 2: World 7-Year Perspective for Drug Discovery
Informatics by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World Markets for Years 2020 & 2027

Table 3: World Current & Future Analysis for Sequencing &
Target Data Analysis by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 4: World 7-Year Perspective for Sequencing & Target Data
Analysis by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World for Years 2020 & 2027

Table 5: World Current & Future Analysis for Docking by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 6: World 7-Year Perspective for Docking by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2020 & 2027

Table 7: World Current & Future Analysis for Molecular
Modelling by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 8: World 7-Year Perspective for Molecular Modelling by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

Table 9: World Current & Future Analysis for Library
Preparation by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Thousand for Years 2020 through
2027 and % CAGR

Table 10: World 7-Year Perspective for Library Preparation by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

Table 11: World Current & Future Analysis for Other Functions
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 12: World 7-Year Perspective for Other Functions by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

Table 13: World Current & Future Analysis for Software by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 14: World 7-Year Perspective for Software by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2020 & 2027

Table 15: World Current & Future Analysis for Services by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 16: World 7-Year Perspective for Services by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2020 & 2027

Table 17: World Current & Future Analysis for Pharmaceutical &
Biotechnology Companies by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 18: World 7-Year Perspective for Pharmaceutical &
Biotechnology Companies by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2020 & 2027

Table 19: World Current & Future Analysis for Contract Research
Organizations (CROS) by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Thousand for Years
2020 through 2027 and % CAGR

Table 20: World 7-Year Perspective for Contract Research
Organizations (CROS) by Geographic Region - Percentage
Breakdown of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2020 & 2027

Table 21: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Thousand for Years 2020 through 2027 and
% CAGR

Table 22: World 7-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Dwindling Government Funding Support for Healthcare R&D, A
Major Challenge for Growth in the Country
Table 23: USA Current & Future Analysis for Drug Discovery
Informatics by Function - Sequencing & Target Data Analysis,
Docking, Molecular Modelling, Library Preparation and Other
Functions - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 24: USA 7-Year Perspective for Drug Discovery Informatics
by Function - Percentage Breakdown of Value Sales for
Sequencing & Target Data Analysis, Docking, Molecular
Modelling, Library Preparation and Other Functions for the
Years 2020 & 2027

Table 25: USA Current & Future Analysis for Drug Discovery
Informatics by Solution - Software and Services - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 26: USA 7-Year Perspective for Drug Discovery Informatics
by Solution - Percentage Breakdown of Value Sales for Software
and Services for the Years 2020 & 2027

Table 27: USA Current & Future Analysis for Drug Discovery
Informatics by End-Use - Pharmaceutical & Biotechnology
Companies, Contract Research Organizations (CROS) and Other
End-Uses - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 28: USA 7-Year Perspective for Drug Discovery Informatics
by End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, Contract Research
Organizations (CROS) and Other End-Uses for the Years 2020 &
2027

CANADA
Table 29: Canada Current & Future Analysis for Drug Discovery
Informatics by Function - Sequencing & Target Data Analysis,
Docking, Molecular Modelling, Library Preparation and Other
Functions - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 30: Canada 7-Year Perspective for Drug Discovery
Informatics by Function - Percentage Breakdown of Value Sales
for Sequencing & Target Data Analysis, Docking, Molecular
Modelling, Library Preparation and Other Functions for the
Years 2020 & 2027

Table 31: Canada Current & Future Analysis for Drug Discovery
Informatics by Solution - Software and Services - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 32: Canada 7-Year Perspective for Drug Discovery
Informatics by Solution - Percentage Breakdown of Value Sales
for Software and Services for the Years 2020 & 2027

Table 33: Canada Current & Future Analysis for Drug Discovery
Informatics by End-Use - Pharmaceutical & Biotechnology
Companies, Contract Research Organizations (CROS) and Other
End-Uses - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 34: Canada 7-Year Perspective for Drug Discovery
Informatics by End-Use - Percentage Breakdown of Value Sales
for Pharmaceutical & Biotechnology Companies, Contract Research
Organizations (CROS) and Other End-Uses for the Years 2020 &
2027

JAPAN
Table 35: Japan Current & Future Analysis for Drug Discovery
Informatics by Function - Sequencing & Target Data Analysis,
Docking, Molecular Modelling, Library Preparation and Other
Functions - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 36: Japan 7-Year Perspective for Drug Discovery
Informatics by Function - Percentage Breakdown of Value Sales
for Sequencing & Target Data Analysis, Docking, Molecular
Modelling, Library Preparation and Other Functions for the
Years 2020 & 2027

Table 37: Japan Current & Future Analysis for Drug Discovery
Informatics by Solution - Software and Services - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 38: Japan 7-Year Perspective for Drug Discovery
Informatics by Solution - Percentage Breakdown of Value Sales
for Software and Services for the Years 2020 & 2027

Table 39: Japan Current & Future Analysis for Drug Discovery
Informatics by End-Use - Pharmaceutical & Biotechnology
Companies, Contract Research Organizations (CROS) and Other
End-Uses - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 40: Japan 7-Year Perspective for Drug Discovery
Informatics by End-Use - Percentage Breakdown of Value Sales
for Pharmaceutical & Biotechnology Companies, Contract Research
Organizations (CROS) and Other End-Uses for the Years 2020 &
2027

CHINA
Table 41: China Current & Future Analysis for Drug Discovery
Informatics by Function - Sequencing & Target Data Analysis,
Docking, Molecular Modelling, Library Preparation and Other
Functions - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 42: China 7-Year Perspective for Drug Discovery
Informatics by Function - Percentage Breakdown of Value Sales
for Sequencing & Target Data Analysis, Docking, Molecular
Modelling, Library Preparation and Other Functions for the
Years 2020 & 2027

Table 43: China Current & Future Analysis for Drug Discovery
Informatics by Solution - Software and Services - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 44: China 7-Year Perspective for Drug Discovery
Informatics by Solution - Percentage Breakdown of Value Sales
for Software and Services for the Years 2020 & 2027

Table 45: China Current & Future Analysis for Drug Discovery
Informatics by End-Use - Pharmaceutical & Biotechnology
Companies, Contract Research Organizations (CROS) and Other
End-Uses - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 46: China 7-Year Perspective for Drug Discovery
Informatics by End-Use - Percentage Breakdown of Value Sales
for Pharmaceutical & Biotechnology Companies, Contract Research
Organizations (CROS) and Other End-Uses for the Years 2020 &
2027

EUROPE
Table 47: Europe Current & Future Analysis for Drug Discovery
Informatics by Geographic Region - France, Germany, Italy, UK
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 48: Europe 7-Year Perspective for Drug Discovery
Informatics by Geographic Region - Percentage Breakdown of
Value Sales for France, Germany, Italy, UK and Rest of Europe
Markets for Years 2020 & 2027

Table 49: Europe Current & Future Analysis for Drug Discovery
Informatics by Function - Sequencing & Target Data Analysis,
Docking, Molecular Modelling, Library Preparation and Other
Functions - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 50: Europe 7-Year Perspective for Drug Discovery
Informatics by Function - Percentage Breakdown of Value Sales
for Sequencing & Target Data Analysis, Docking, Molecular
Modelling, Library Preparation and Other Functions for the
Years 2020 & 2027

Table 51: Europe Current & Future Analysis for Drug Discovery
Informatics by Solution - Software and Services - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 52: Europe 7-Year Perspective for Drug Discovery
Informatics by Solution - Percentage Breakdown of Value Sales
for Software and Services for the Years 2020 & 2027

Table 53: Europe Current & Future Analysis for Drug Discovery
Informatics by End-Use - Pharmaceutical & Biotechnology
Companies, Contract Research Organizations (CROS) and Other
End-Uses - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 54: Europe 7-Year Perspective for Drug Discovery
Informatics by End-Use - Percentage Breakdown of Value Sales
for Pharmaceutical & Biotechnology Companies, Contract Research
Organizations (CROS) and Other End-Uses for the Years 2020 &
2027

FRANCE
Table 55: France Current & Future Analysis for Drug Discovery
Informatics by Function - Sequencing & Target Data Analysis,
Docking, Molecular Modelling, Library Preparation and Other
Functions - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 56: France 7-Year Perspective for Drug Discovery
Informatics by Function - Percentage Breakdown of Value Sales
for Sequencing & Target Data Analysis, Docking, Molecular
Modelling, Library Preparation and Other Functions for the
Years 2020 & 2027

Table 57: France Current & Future Analysis for Drug Discovery
Informatics by Solution - Software and Services - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 58: France 7-Year Perspective for Drug Discovery
Informatics by Solution - Percentage Breakdown of Value Sales
for Software and Services for the Years 2020 & 2027

Table 59: France Current & Future Analysis for Drug Discovery
Informatics by End-Use - Pharmaceutical & Biotechnology
Companies, Contract Research Organizations (CROS) and Other
End-Uses - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 60: France 7-Year Perspective for Drug Discovery
Informatics by End-Use - Percentage Breakdown of Value Sales
for Pharmaceutical & Biotechnology Companies, Contract Research
Organizations (CROS) and Other End-Uses for the Years 2020 &
2027

GERMANY
Table 61: Germany Current & Future Analysis for Drug Discovery
Informatics by Function - Sequencing & Target Data Analysis,
Docking, Molecular Modelling, Library Preparation and Other
Functions - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 62: Germany 7-Year Perspective for Drug Discovery
Informatics by Function - Percentage Breakdown of Value Sales
for Sequencing & Target Data Analysis, Docking, Molecular
Modelling, Library Preparation and Other Functions for the
Years 2020 & 2027

Table 63: Germany Current & Future Analysis for Drug Discovery
Informatics by Solution - Software and Services - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 64: Germany 7-Year Perspective for Drug Discovery
Informatics by Solution - Percentage Breakdown of Value Sales
for Software and Services for the Years 2020 & 2027

Table 65: Germany Current & Future Analysis for Drug Discovery
Informatics by End-Use - Pharmaceutical & Biotechnology
Companies, Contract Research Organizations (CROS) and Other
End-Uses - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 66: Germany 7-Year Perspective for Drug Discovery
Informatics by End-Use - Percentage Breakdown of Value Sales
for Pharmaceutical & Biotechnology Companies, Contract Research
Organizations (CROS) and Other End-Uses for the Years 2020 &
2027

ITALY
Table 67: Italy Current & Future Analysis for Drug Discovery
Informatics by Function - Sequencing & Target Data Analysis,
Docking, Molecular Modelling, Library Preparation and Other
Functions - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 68: Italy 7-Year Perspective for Drug Discovery
Informatics by Function - Percentage Breakdown of Value Sales
for Sequencing & Target Data Analysis, Docking, Molecular
Modelling, Library Preparation and Other Functions for the
Years 2020 & 2027

Table 69: Italy Current & Future Analysis for Drug Discovery
Informatics by Solution - Software and Services - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 70: Italy 7-Year Perspective for Drug Discovery
Informatics by Solution - Percentage Breakdown of Value Sales
for Software and Services for the Years 2020 & 2027

Table 71: Italy Current & Future Analysis for Drug Discovery
Informatics by End-Use - Pharmaceutical & Biotechnology
Companies, Contract Research Organizations (CROS) and Other
End-Uses - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 72: Italy 7-Year Perspective for Drug Discovery
Informatics by End-Use - Percentage Breakdown of Value Sales
for Pharmaceutical & Biotechnology Companies, Contract Research
Organizations (CROS) and Other End-Uses for the Years 2020 &
2027

UNITED KINGDOM
Table 73: UK Current & Future Analysis for Drug Discovery
Informatics by Function - Sequencing & Target Data Analysis,
Docking, Molecular Modelling, Library Preparation and Other
Functions - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 74: UK 7-Year Perspective for Drug Discovery Informatics
by Function - Percentage Breakdown of Value Sales for
Sequencing & Target Data Analysis, Docking, Molecular
Modelling, Library Preparation and Other Functions for the
Years 2020 & 2027

Table 75: UK Current & Future Analysis for Drug Discovery
Informatics by Solution - Software and Services - Independent
Analysis of Annual Sales in US$ Thousand for the Years 2020
through 2027 and % CAGR

Table 76: UK 7-Year Perspective for Drug Discovery Informatics
by Solution - Percentage Breakdown of Value Sales for Software
and Services for the Years 2020 & 2027

Table 77: UK Current & Future Analysis for Drug Discovery
Informatics by End-Use - Pharmaceutical & Biotechnology
Companies, Contract Research Organizations (CROS) and Other
End-Uses - Independent Analysis of Annual Sales in US$ Thousand
for the Years 2020 through 2027 and % CAGR

Table 78: UK 7-Year Perspective for Drug Discovery Informatics
by End-Use - Percentage Breakdown of Value Sales for
Pharmaceutical & Biotechnology Companies, Contract Research
Organizations (CROS) and Other End-Uses for the Years 2020 &
2027

REST OF EUROPE
Table 79: Rest of Europe Current & Future Analysis for Drug
Discovery Informatics by Function - Sequencing & Target Data
Analysis, Docking, Molecular Modelling, Library Preparation and
Other Functions - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 80: Rest of Europe 7-Year Perspective for Drug Discovery
Informatics by Function - Percentage Breakdown of Value Sales
for Sequencing & Target Data Analysis, Docking, Molecular
Modelling, Library Preparation and Other Functions for the
Years 2020 & 2027

Table 81: Rest of Europe Current & Future Analysis for Drug
Discovery Informatics by Solution - Software and Services -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 82: Rest of Europe 7-Year Perspective for Drug Discovery
Informatics by Solution - Percentage Breakdown of Value Sales
for Software and Services for the Years 2020 & 2027

Table 83: Rest of Europe Current & Future Analysis for Drug
Discovery Informatics by End-Use - Pharmaceutical &
Biotechnology Companies, Contract Research Organizations (CROS)
and Other End-Uses - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 84: Rest of Europe 7-Year Perspective for Drug Discovery
Informatics by End-Use - Percentage Breakdown of Value Sales
for Pharmaceutical & Biotechnology Companies, Contract Research
Organizations (CROS) and Other End-Uses for the Years 2020 &
2027

ASIA-PACIFIC
Table 85: Asia-Pacific Current & Future Analysis for Drug
Discovery Informatics by Function - Sequencing & Target Data
Analysis, Docking, Molecular Modelling, Library Preparation and
Other Functions - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 86: Asia-Pacific 7-Year Perspective for Drug Discovery
Informatics by Function - Percentage Breakdown of Value Sales
for Sequencing & Target Data Analysis, Docking, Molecular
Modelling, Library Preparation and Other Functions for the
Years 2020 & 2027

Table 87: Asia-Pacific Current & Future Analysis for Drug
Discovery Informatics by Solution - Software and Services -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 88: Asia-Pacific 7-Year Perspective for Drug Discovery
Informatics by Solution - Percentage Breakdown of Value Sales
for Software and Services for the Years 2020 & 2027

Table 89: Asia-Pacific Current & Future Analysis for Drug
Discovery Informatics by End-Use - Pharmaceutical &
Biotechnology Companies, Contract Research Organizations (CROS)
and Other End-Uses - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 90: Asia-Pacific 7-Year Perspective for Drug Discovery
Informatics by End-Use - Percentage Breakdown of Value Sales
for Pharmaceutical & Biotechnology Companies, Contract Research
Organizations (CROS) and Other End-Uses for the Years 2020 &
2027

REST OF WORLD
Table 91: Rest of World Current & Future Analysis for Drug
Discovery Informatics by Function - Sequencing & Target Data
Analysis, Docking, Molecular Modelling, Library Preparation and
Other Functions - Independent Analysis of Annual Sales in US$
Thousand for the Years 2020 through 2027 and % CAGR

Table 92: Rest of World 7-Year Perspective for Drug Discovery
Informatics by Function - Percentage Breakdown of Value Sales
for Sequencing & Target Data Analysis, Docking, Molecular
Modelling, Library Preparation and Other Functions for the
Years 2020 & 2027

Table 93: Rest of World Current & Future Analysis for Drug
Discovery Informatics by Solution - Software and Services -
Independent Analysis of Annual Sales in US$ Thousand for the
Years 2020 through 2027 and % CAGR

Table 94: Rest of World 7-Year Perspective for Drug Discovery
Informatics by Solution - Percentage Breakdown of Value Sales
for Software and Services for the Years 2020 & 2027

Table 95: Rest of World Current & Future Analysis for Drug
Discovery Informatics by End-Use - Pharmaceutical &
Biotechnology Companies, Contract Research Organizations (CROS)
and Other End-Uses - Independent Analysis of Annual Sales in
US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 96: Rest of World 7-Year Perspective for Drug Discovery
Informatics by End-Use - Percentage Breakdown of Value Sales
for Pharmaceutical & Biotechnology Companies, Contract Research
Organizations (CROS) and Other End-Uses for the Years 2020 &
2027

IV. COMPETITION
Total Companies Profiled: 41